GlaxoSmithKline Receives FDA Approval Of An Additional Promacta Indication For Use In Patients With Severe Aplastic Anaemia Who Have Had An Insufficient Response To Immunosuppressive Therapy - New first-in-class treatment option for this previously treated SAA patient population- GlaxoSmithKline plc announced today that the U.S. Food and Drug ... (more)
http://ift.tt/1mOD7sp
http://ift.tt/1mOD7sp
No comments:
Post a Comment